At Ignyta, we fight cancer – a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally, every year. In this fight, our vision is not just to shrink tumors but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations by 2030. We will work tirelessly to achieve this vision by pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Our Rx efforts are focused on discovering, in-licensing or acquiring, then developing and commercializing, molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Our Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies we develop. We believe that only through this integrated Rx/Dx approach can we succeed in this fight.
Company Growth (employees)
San Diego, US
Size (employees)
115 (est)+10%
Ignyta was founded in 2011 and is headquartered in San Diego, US

Ignyta Office Locations

Ignyta has an office in San Diego
San Diego, US (HQ)
11095 Flintkote Ave

Ignyta Data and Metrics

Ignyta Financial Metrics

Ignyta's revenue was reported to be $0 in Q1, 2016

Net income (Q1, 2017)

(40.2 m)

EBIT (Q1, 2017)

(39.6 m)

Market capitalization (15-Aug-2017)

485.6 m

Cash (31-Dec-2016)

24.3 m
Ignyta's current market capitalization is $485.6 m.
USDY, 2013FY, 2014FY, 2015FY, 2016


150 k

Revenue growth, %



(13.9 m)

Pre tax profit

(14.2 m)

Net Income

(14.2 m)(40 m)(92.5 m)(103.6 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


150 k

R&D expense

8.8 m10.4 m19.8 m20 m16.6 m34 m

General and administrative expense

3.9 m3.9 m5.2 m5.5 m6.1 m5.6 m

Operating expense total

12.7 m14.3 m25 m25.5 m22.8 m39.6 m


(12.7 m)(14.3 m)(25 m)(25.5 m)(22.8 m)(39.6 m)

EBIT margin, %


Interest expense

(603.1 k)(580 k)(790 k)(800 k)(814 k)(812 k)

Net Income

(13.1 m)(14.6 m)(25.5 m)(26.7 m)(23.3 m)(40.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


51.8 m6.3 m46.4 m24.3 m


1.7 m4.4 m

Current Assets

52.5 m71.3 m136.2 m111.9 m


18.8 m6.3 m

Total Assets

53.3 m85.3 m196.1 m144.9 m

Accounts Payable

975.3 k3.8 m13.5 m

Current Liabilities

1.5 m7.5 m24.8 m17.5 m

Total Liabilities

50.1 m

Additional Paid-in Capital

57.4 m111.6 m284.3 m346.5 m

Retained Earnings

(55.6 m)(148 m)(251.7 m)

Total Equity

41.8 m55.9 m136 m94.8 m

Financial Leverage

1.3 x1.5 x1.4 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(14.2 m)(40 m)(92.5 m)(103.6 m)

Depreciation and Amortization

112.4 k527.7 k


(800.7 k)

Accounts Payable

2.9 m95 k

Cash From Operating Activities

(13.1 m)(32.5 m)(50.8 m)(90.1 m)

Purchases of PP&E

(3.5 m)(2.5 m)

Cash From Investing Activities

(678 k)(74.3 m)(61 m)

Long-term Borrowings

(1.5 m)(10 m)

Cash From Financing Activities

60.5 m61.4 m151.8 m53.8 m

Interest Paid

51.1 k1.9 m2.5 m2.6 m

Income Taxes Paid

2.1 k5.3 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.1 m)(14.6 m)(25.5 m)(26.7 m)(23.3 m)(40.2 m)

Accounts Payable

2 m797.9 k1.8 m1.8 m3.2 m8.8 m1.7 m2.1 m

Ignyta Market Value History

Traffic Overview of Ignyta

Ignyta Online and Social Media Presence

Ignyta Company Life and Culture

You may also be interested in